Novavax Stock News

One of the stock subgroups that's gaining significant attention in today's market is that of Covid-19 vaccine makers. Among today's biggest winners is beaten-down Novavax (NASDAQ: NVAX ).

Novavax, Moderna, Pfizer and its partner BioNTech are slated to roll out new shots designed to target the omicron subvariant XBB.1.5 this fall.

The drugmakers designed their updated coronavirus shots to target the omicron subvariant XBB.1.5, which is slowly declining nationwide.

Novavax posted a surprising profit last quarter as revenue more than doubled. However, the COVID-vaccine maker might not generate much revenue next quarter.

Investors who've dipped their toe into the waters of biotech stocks know that the chances of these stocks crashing and burning is certainly higher than with most sectors. Failure is incredibly common

Three US pharmaceutical companies, Pfizer Inc (NYSE:PFE), Moderna Therapeutics Inc (NASDAQ:MRNA), and Novavax Inc, are gearing up to release updated Covid-19 vaccines this autumn. The new jabs are de

Novavax's prospects in the coronavirus vaccine market look dim. Sage Therapeutics' recent regulatory news was a major blow to its prospects.

A coronavirus subvariant is starting to garner more headlines, leading to greater concern about a surge. The biotech developed one of the three COVID vaccines currently authorized for use in this coun

Investing in growth stocks can be risky, especially for those migrating into new markets or turnaround ventures. Personally, I've experienced losses from such endeavors.

Healthcare continues to lag in the broader market. Year to date, the Standards and Practices (S&P) 500 Health Care index is down 2% versus a 17% gain in the benchmark S&P 500 index.

Novavax (NVAX) reports better-than-expected Q2 earnings results, as earnings and revenues beat estimates. Shares drop due to lowered 2023 product sales guidance.

It's not the only vaccine producer struggling to get by, but Novavax looked terminal earlier this year by its own admission.

Novavax (NVAX) shares closed lower on Tuesday, despite the company reporting a surprise profit in the second quarter. The biotech company's results got a lift from Covid vaccine sales, but it was forc

Novavax, Inc. (NASDAQ:NVAX ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Erika Schultz - Senior Director, IR John Jacob - President and CEO Filip Dubovsky - CMO Joh

Although the revenue and EPS for Novavax (NVAX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street e